Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues
Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...
Why Biohaven Stock Triumphed on Tuesday
News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain ...
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) has ...
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...
Fintel on MSN3d
Deutsche Bank Initiates Coverage of Biohaven (BHVN) with Buy Recommendation
Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Biohaven (NYSE:BHVN) with a Buy recommendation.
Spire Wealth Management Acquires Shares of 1,500 Biohaven Ltd. (NYSE:BHVN)
Spire Wealth Management bought a new position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) during the 4th quarter, ...
Biohaven’s troriluzole NDA in spinocerebellar ataxia accepted by the FDA
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Investor's Business Daily on MSN3d
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.
Celtics Wire16h
West Palm's new office tower One Flagler opens as Related Ross works on other projects
Four years after construction began, the Related Ross company's 25-story luxury One Flagler office tower opened this month in ...
Biohaven Gets FDA Priority Review of Troriluzole for Spinocerebellar Ataxia
Biohaven has won Food and Drug Administration priority review for its application seeking approval of troriluzole for adults with spinocerebellar ataxia, a group of rare, genetic neurological ...